Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases.
暂无分享,去创建一个
F. Ciardiello | F. Morgillo | M. Orditura | E. Lieto | Annamaria Auricchio | Andrea Mabilia | P. Castellano | G. Galizia | A. Renda | F. De Vita | A. Zamboli
[1] M. Orditura,et al. Radiofrequency-Assisted Liver Resection With a Comb-Shaped Bipolar Device Versus Clamp Crushing , 2012, Surgical innovation.
[2] T. Hickish,et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] M. Ducreux,et al. Patients Operated On for Initially Unresectable Colorectal Liver Metastases With Missing Metastases Experience a Favorable Long-Term Outcome , 2011, Annals of surgery.
[4] C. Bokemeyer,et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] E. Van Cutsem,et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] C. Giovane,et al. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer , 2011, British Journal of Cancer.
[7] E. Vasile,et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. , 2011, Journal of the National Cancer Institute.
[8] E. Van Cutsem,et al. Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: The role of anti‐VEGF and anti‐EGFR antibodies , 2010, Journal of surgical oncology.
[9] Josep Tabernero,et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Vauthey,et al. The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. , 2010, Clinical colorectal cancer.
[11] G. Fontanini,et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. , 2010, The Lancet. Oncology.
[12] P. Bachellier,et al. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[13] Markus Klinger,et al. Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX , 2010, Annals of Surgical Oncology.
[14] A. Zhu,et al. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. , 2009, The oncologist.
[15] V. Georgoulias,et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] E. Fisher,et al. Survival after hepatic resection of colorectal cancer metastases , 2009, Cancer.
[17] R. Labianca,et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Orditura,et al. First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. , 2008, Archives of surgery.
[19] F. Lévi,et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Thomas Gruenberger,et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.
[21] P. Tekkis,et al. Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer: A Multifactorial Model of 929 Patients , 2008, Annals of surgery.
[22] A. Carrato,et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. , 2007, European journal of cancer.
[23] P. Tekkis,et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing , 2007, British Journal of Cancer.
[24] C. Lepage,et al. Epidemiology and Management of Liver Metastases From Colorectal Cancer , 2006, Annals of surgery.
[25] S. Curley,et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] C. Köhne,et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] N. Meropol,et al. Changing patterns of bone and brain metastases in patients with colorectal cancer. , 2005, Clinical colorectal cancer.
[28] R. Single,et al. Surgical Resection of Primary Tumors in Patients Who Present With Stage IV Colorectal Cancer: An Analysis of Surveillance, Epidemiology, and End Results Data, 1988 to 2000 , 2005, Annals of Surgical Oncology.
[29] D. Sargent,et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] C. Tournigand,et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J. Weitz,et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. , 2010, The Lancet. Oncology.
[32] R. Parks,et al. Perioperative chemotherapy with FOLFOX 4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer ( EORTC Intergroup trial 40983 ) : a randomised controlled trial , 2008 .